Sinovac Biotech, Ltd (SVA) Misses Q3 EPS by 3c

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q3 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $12.35 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30